Molecular mechanisms of prostate cancer

Kati P Porkka; Tapio Visakorpi

doi:10.1016/j.eururo.2004.01.012

Molecular mechanisms of prostate cancer

Eur Urol. 2004 Jun;45(6):683-91. doi: 10.1016/j.eururo.2004.01.012.

Authors

Kati P Porkka¹, Tapio Visakorpi

Affiliation

¹ Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere, and Tampere University Hospital, Biokatu 6, FIN-33520 Tampere, Finland.

PMID: 15149739
DOI: 10.1016/j.eururo.2004.01.012

Abstract

During the last ten years our knowledge of genetic alterations in prostate cancer has significantly increased. For example, several chromosomal loci possibly harboring predisposing or somatically mutated genes have been suggested. Still, we lack the comprehensive molecular model for the development and progression of prostate cancer. Only a few genes have been found to be aberrant in a significant proportion of prostate cancer. These include GSTP1, PTEN, TP53, and AR. Thus, they are natural targets for new treatment strategies.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Acyltransferases / genetics
Chromosome Mapping
Forecasting
Genetic Predisposition to Disease
Homeodomain Proteins / genetics
Humans
Male
Molecular Biology / trends
PTEN Phosphohydrolase
Phosphoric Monoester Hydrolases / genetics
Prostatic Neoplasms / genetics*
Receptors, Androgen / genetics
Transcription Factors / genetics
Tumor Suppressor Protein p53 / genetics
Tumor Suppressor Proteins / genetics

Substances

Homeodomain Proteins
NKX3-1 protein, human
Receptors, Androgen
Transcription Factors
Tumor Suppressor Protein p53
Tumor Suppressor Proteins
Acyltransferases
fatty acyl ethyl ester synthase
Phosphoric Monoester Hydrolases
PTEN Phosphohydrolase
PTEN protein, human